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This the case of a 63 year-old man with end-stage renal disease (on chronic hemodialysis), unstable angina and sig-
nificantly impaired myocardial contractility with low left ventricular ejection fraction, who underwent off-pump one
vessel coronary bypass surgery. Combined continuous levosimendan and norepinephrine infusion (at 0.07 μg/kg/min
and 0.05 μg/kg/min respectively) started immediately after anesthesia induction and continued for 24 hours. The
levosimendan/norepinephrine combination helped maintain an appropriate hemodynamic profile, thereby contribut-
ing to uneventful completion of surgery and postoperative hemodynamic stability. Although levosimendan is consid-
ered contraindicated in ESRD patients, this case report suggests that combined perioperative levosimendan/
norepinephrine administration can be useful in carefully selected hemodialysis patients with impaired myocardial
contractility and ongoing myocardial ischemia, who undergo off-pump myocardial revascularization surgery.
Background
Levosimendan (OR 1259), the levo-isomer of racemic
simendan [1] is a pharmacologic agent indicated for treat-
ment of non-compensated heart failure. Levosimendan
enhances myocardial contractility without increasing myo-
cardial oxygen consumption [2,3] through two different
mechanisms: (A) calcium-dependent binding to cardiac
troponin C, thereby enhancing the calcium sensitivity of
cardiac contractile proteins [3,4] and improving myocar-
dial contractility, and (B) opening of ATP-dependent
potassium channels in vascular smooth muscle, resulting
in venous, arterial and coronary vasodilation [5-8], thereby
reducing myocardial preload and afterload.
Levosimendan is 98% albumin-bound, its volume of
distribution is 0.4 L/kg, plasma half life is 1 hour [9], and
plasma clearance is 3 ml/kg/min [10,11]. Peak plasma
concentrations occur 12 minutes after a bolus dose or 4
hours after starting a continuous infusion without a
bolus. Levosimendan is extensively metabolized in the
liver, is eliminated mainly by conjugation and excretion
in urine and feces, and its elimination half-life is 1 hour
[12]. After IV levosimendan administration, 5% of the
drug is reduced in the small bowel to OR-1855, which is
reabsorbed to the systemic circulation, and is then meta-
bolized to OR-1896, which is pharmacologically active
and produces a hemodynamic profile comparable to the
parent-drug. OR-1896 is only 40% protein-bound, its
peak plasma concentration is observed 1-4 days after
levosimendan infusion ends [10], its half life is 80 hours,
and it is responsible for the extended (7-9 days) duration
of levosimendan clinical action [5,12-14].
Levosimendan is not dialyzable. In contrast, OR-1855
and OR-1896 are dialyzable, but their dialysis clearance
is very slow (8-23 ml/minute). Consequently, the net
effect of a 4-hour hemodialysis session on exposure to
active metabolites is limited [3], and the AUCs for
OR-1855 and OR-1896 are increased by 170% in hemo-
dialysis patients. Although the Levosimendan package
insert [3] states that levosimendan should not be used
in ESRD patients, there is one case report of postopera-
tive use [13], but no reports of intraoperative levosimen-
dan use in hemodialysis patients. In this case report we
describe a hemodialysis patient with severe CAD,
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therapy, low LVEF and severe bilateral ICA stenosis.
The patient received a 24-hour continuous IV levosi-
mendan/norepinephrine infusion during and after
OPCAB surgery, with very satisfactory results: myocar-
dial contractility, CO, CI, SvO2 and INVOS markedly
improved, and there was no hypotension or exacerba-
tion of myocardial ischemia.
Case presentation
A 63 year-old Caucasian man with unstable angina and
chronic renal failure underwent one vessel OPCAB. Past
medical history included smoking 2 packs per day for
40 years, hypertension, IDDM treated with insulin for
15 years, PVD with claudication and bilateral ICA steno-
sis, ESRD (Cr: 8.4 mg/dL, BUN: 199 mg/dL) which had
been attributed to long-standing poorly controlled
hypertension, and was treated with periodic (every other
day) hemodialysis for 6 years, and sick sinus syndrome.
He had a pacemaker (programmed in DDD mode with
b a s e l i n eH Rs e ta t6 0 / m i n u t e )i n s e r t e dt h r e ey e a r s
before this myocardial revascularization procedure, but
the pacemaker was turned off immediately after anesthe-
sia induction. He also had intermittent claudication,
with preoperative angiography revealing significant right
iliac and left femoral artery stenosis, extensive abdom-
inal aorta calcification and 80% bilateral ICA stenosis.
Coronary angiography revealed 3-vessel disease, with
80% mid-LAD stenosis, complete proximal and distal
LCX occlusion with retrograde filling from the LAD,
and complete ostial RCA occlusion. Transthoracic echo-
cardiography revealed LV dilatation with akinetic basal
inferior and basal posterior LV wall, hypokinetic medial
posterior LV wall, LVEF estimated at 25-30%, moderate
mitral regurgitation and pulmonary hypertension (esti-
mated peak PA pressure 58 mmHg). In the last week
before surgery, the patient had difficulty completing
hemodialysis sessions due to serious hypotension, and
experienced unstable angina, while under maximal med-
ical therapy with nitrates (transdermal glyceryl trinitrate
10 mg per 24 hours), ACE inhibitors (p.o. enalapril 10
mg per day) and aspirin (p.o. 325 mg per day). Because
of his unstable condition, we decided to proceed with
myocardial revascularization only, and consider surgical
treatment of bilateral ICA stenosis later. Furthermore,
we chose the OPCAB technique, in order to lower the
risk of adverse cerebral events and avoid the undesirable
consequences of cardiopulmonary bypass. Monitoring
included, in addition to the standard monitors mandated
by the American Society of Anesthesiologists, invasive
blood pressure through a right radial arterial line, CVP,
PA and PAOP pressures through a PA catheter, which
was inserted immediately after induction of anesthesia
and was removed on the 2
nd postoperative day. We also
used INVOS (Cerebral Oximeter System, Somanetics),
with sensors attached to the patient’s forehead, to moni-
tor adequacy of cerebral perfusion, and TEE to monitor
myocardial contractility. Anesthesia induction was
uneventful, without any hemodynamic derangement.
Mean arterial pressure was maintained at 60 mmHg or
higher, while the PA catheter revealed pulmonary hyper-
tension (SPAP: 56 mmHg, PAOP: 18 mmHg, CVP: 18
mmHg, CO: 2.8 L/min, CI: 1.6 L/m
2/min SvO2 49%,
SVR 1114). As direct visualization of the heart con-
firmed severely impaired myocardial contractility with
abnormal distension of both ventricles, we decided to
start inotropic support using a combined levosimendan/
norepinephrine infusion in an attempt to improve myo-
cardial function and increase cardiac output, while
avoiding myocardial ischemia and hypotension. The
decision to use a levosimendan/norepinephrine combi-
nation was based on the need to (A) improve myocar-
dial contractility and cardiac output without increasing
myocardial oxygen consumption, and (B) avoid hypoten-
sion, which could aggravate myocardial and brain ische-
mia. Because of hypoalbuminemia, we started IV
levosimendan infusion at only 0.07 μg/kg/min, while IV
norepinephrine infusion started at 0.05 μg/kg/min and
was titrated to effect. Baseline INVOS values were very
low before anesthesia induction (42 on the left, 37 on
the right side) and increased only slightly after anesthe-
sia induction (45 on the left, 43 on the right side). How-
ever, thirty minutes after levosimendan infusion started,
CO, CI and SvO2 improved significantly (to 3.6 L/min,
2.1 L/m
2/min and 70% respectively), LVEF increased to
50% and INVOS also increased significantly (to 59 on
the left, 53 on the right). Despite the need to gradually
increase norepinephrine dose to 0.15 μg/kg/min, in
order to maintain MAP >60 mmHg, CI and SvO2 con-
tinued to rise, while CVP, PA and PAOP declined
slightly over the ensuing 3 hours (while surgery was still
underway), and this improvement persisted during the
entire postoperative period (table 1). Accidental intrao-
perative rupture of the very thin anterior RV wall
resulted in hemodynamic collapse, requiring prompt,
rapid administration of 5 units of red blood cells,
2 units of FFP and addition of epinephrine infusion at
0.07 μg/kg/min. Hypotension lasted approximately
30 minutes, until the RV wall rupture was securely cor-
rected (without requiring extracorporeal circulation).
Postoperatively, the patient was transferred to the ICU,
where levosimendan infusion continued for 24 hours
and norepinephrine continued for 40 hours. The patient
was extubated on POD 1, and had uneventful hemodia-
lysis a few hours after extubation. Detailed postoperative
neurologic examination did not reveal any neurologic
deficits. Vital signs remained stable postoperatively,
except for an episode of hypotension shortly after
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with volume loading, and was attributed to pericardial
effusion, which delayed discharge from the hospital until
POD 12. Three months later, the patient was in good
condition, had a normal life and continued hemodialysis
three times/week without any problems. Follow-up
echocardiography 4 months after the operation showed
somewhat improved myocardial contractility, with LVEF
estimated at 40%, mild mitral regurgitation and esti-
mated peak pulmonary artery pressure at 35 mmHg.
Now, three years later, he is still alive and doing
remarkably well.
Conclusions
Levosimendan is a newer therapeutic agent for treat-
ment of cardiac failure [13], is generally well tolerated,
and its main side effects are usually due to vasodilation.
Although levosimendan has been administered to
patients with mild to moderate renal disease without
serious adverse consequences [14], we could find only
one published case of postoperative (but not intraopera-
tive) levosimendan administration in a hemodialysis
patient [13]. Despite the absence of published data, we
decided to use levosimendan in our patient, because he
had significantly impaired LV function, low CO, CI and
SvO2, and evidence of impaired cerebral oxygenation, as
measured by INVOS. We therefore needed to improve
myocardial contractility, CO, CI and SvO2 without
increasing myocardial oxygen consumption and without
hypotension, which could be detrimental, due to severe
bilateral ICA stenosis. Under the circumstances, com-
bined levosimendan/norepinephrine use was a reason-
able choice: levosimendan improves myocardial
contractility without increasing myocardial oxygen con-
sumption [15-17], while norepinephrine has desirable
inotropic and vasopressor properties. Use of IABP could
also be a reasonable option, but insertion of IABP in
this particular patient would be problematic due to
extensive peripheral arterial (aortic, iliac and femoral)
calcification and stenosis, and could further compromise
lower extremity circulation. Dobutamine, milrinone and/
or epinephrine could also improve myocardial contracti-
lity, but would likely increase myocardial oxygen con-
sumption, and thereby exacerbate myocardial ischemia.
In our case, the levosimendan/norepineprhine combina-
tion worked as predicted, conferred significant hemody-
namic improvement (despite unexpected surgical
complications necessitating rapid intraoperative RBC
Table 1 Hemodynamic and INVOS data
T1 T2 T3 T4 T5 T6 T7 T8 T9 T10
HR 60 62 64 64 61 64 65 66 63 68
Psyst 100 125 104 113 108 97 101 110 91 106
Pdiast 45 71 51 61 58 52 51 58 48 55
MAP 57 91 61 80 76 69 70 83 67 70
CVP 18 18 17 16 16 14 15 12 10 10
PAPsyst 56 48 46 46 44 44 40 39 31 35
PAPdiast 25 18 17 17 17 19 20 17 19 17
PAPmean 37 30 30 30 25 25 26 23 24 24
PAOP 18 17 16 16 16 16 16 16 15
CO 2.8 3.6 4.1 4.2 4.0 4.6 4.3 4.6 4.6 4.6
CI 1.6 2.1 2.4 2.4 2.0 2.7 2.5 2.7 2.7 2.7
SVR 1114 1622 858 1219 1200 956 1023 1234 991 1043
PVR 266 253 266 180 156 186 121 139 156
LVEF 25 40 40
SvO2 49 70 80 80 82 82 80 60 65 58
INVOSLeft 45 59 59 55 60 60
FiO2 0.5 0.5 0.5 0.5 0.5 0.6 0.6 0.4 0.4 0.21
Norepinephrine* 0.05 0.08 0.12 0.15 0.12 0.15 0.2 0.08 0.02
* Dose in μg/kg/min
HR in beats/minute
Psyst, Pdiast, P mean, CVP, PAPsyst, PAPdiast, PAPmean, PCWP, all measured in mmHg
CO = L/min, CI = L/m
2/min SVO2 =% ,I N V O S=%
T1 before levosimendan/norepinephrine infusion started
T2 1 h after levosimendan infusion started
T3,T 4 2 and 3 hours after levosimendan infusion started
T5 at end of surgery
T6 T7 6 and 12 hours after surgery
T8, T9, T10 18, 24, 36 hours after surgery
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OPCAB procedure without need for extracorporeal cir-
culation. Thus the patient benefitted from improved
myocardial contractility, increased CO, CI and SvO2 and
reduced CVP and PAOP, and these beneficial changes
lasted for several days after levosimendan infusion
stopped. We believe that the effectiveness of levosimen-
dan at this low dose (0.07 μg/kg/min) was due to
reduced protein binding because of hypoalbuminemia
(albumin plasma level was 3.1 mg/dL in this case). In
addition, the use of a low levosimendan dose, the com-
bination with norepinephrine and close monitoring, in
an attempt to avoid or promptly treat hypotension, all
likely contributed to hemodynamic stability in this case.
In conclusion, this case report suggests that combined
levosimedan/norepinephrine IV infusion is a reasonable
inotropic support option in patients with heart failure
and ongoing myocardial ischemia, even in the presence
of end-stage renal disease and severe bilateral internal
carotid artery stenosis.
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